Fenebrutinib, Genentech’s investigational BTK inhibitor, was found to significantly reduce relapse rates compared with the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials involving people with relapsing forms of multiple sclerosis (MS). Positive top-line results from one of those trials, FENhance 2 (NCT04586023),…
fenebrutinib
The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis (PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib’s developer, Genentech, the therapy is the…
Recommended Posts
- Poor sleep in MS linked to slower removal of brain waste
- Relapsing-remitting MS patients may have less diverse gut bacteria
- New MS cell therapy safely retrains immune system to tolerate myelin
- €1.1M grant moves novel skin patch for MS closer to first human trial
- Automated speech analysis may track MS brain atrophy over time